EMBECTA CORP. (EMBC) Operating Margin
- Operating margin · 12 months: Value 21.94%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 21.94% | Operating income / revenue. Period ending 2026-06-30. $223.50M ÷ $1.02B × 100 ≈ 21.94% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 223.50M USD | Operating Income (Loss) |
| Revenue | 1.02B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 417.40M USD | Cost of Goods and Services Sold |
| Research and development | 20.20M USD | Research and Development Expense |
| Selling, general and administration | 319.30M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $223.50M | $1.02B | $417.40M | $20.20M | $319.30M | 21.94% |
| 2026-03-31 | $268.80M | $1.04B | $397.40M | $19.00M | $325.10M | 25.78% |
| 2025-12-31 | $296.70M | $1.08B | $398.30M | $21.60M | $328.50M | 27.48% |
| 2025-09-30 | $242.10M | $1.08B | $403.60M | $37.30M | $332.00M | 22.41% |
| 2025-06-30 | $211.80M | $1.10B | $410.40M | $52.50M | $341.90M | 19.21% |
| 2025-03-31 | $173.70M | $1.08B | $394.40M | $68.50M | $343.20M | 16.09% |
| 2024-12-31 | $150.00M | $1.11B | $401.30M | $78.90M | $355.90M | 13.54% |
| 2024-09-30 | $166.80M | $1.12B | $387.90M | $78.80M | $365.10M | 14.85% |
| 2024-06-30 | $166.40M | $1.12B | $375.70M | $82.60M | $364.00M | 14.87% |
| 2024-03-31 | $161.80M | $1.13B | $389.90M | $84.80M | $365.90M | 14.29% |
| 2023-12-31 | $178.20M | $1.12B | $375.40M | $88.50M | $358.80M | 15.88% |
| 2023-09-30 | $221.50M | $1.12B | $370.90M | $85.20M | $341.30M | 19.76% |
| 2023-06-30 | $192.70M | $1.11B | $368.50M | $79.50M | $327.50M | 17.31% |
| 2023-03-31 | $238.50M | $1.12B | $360.10M | $71.20M | $323.70M | 21.32% |
| 2022-12-31 | $281.80M | $1.12B | $356.10M | $67.10M | $305.40M | 25.25% |
| 2022-09-30 | $309.60M | $1.13B | $354.60M | $66.90M | $294.80M | 27.41% |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $492.00M | $1.17B | $364.90M | $63.30M | $240.30M | 42.22% |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $486.50M | $1.09B | $322.90M | $61.40M | $214.70M | 44.82% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |